1. Henningfield, J. The brain in withdrawal; neuroscience of treatment.
Symposium presentation. Septiembre de 2008.
2. Boyle, J, Durcan MJ, et al. Efficacy of a nicotine (4mg) containing
lozenge on the cognitive impairment of nicotine withdrawal. Poster
presentado en la reunion europea annual de la Sociedad para la
Investigación sobre la Nicotina y el Tabaco, Padua, Italy.
3. Matthews, P. Imaging brain cognitive effects of nicotine withdrawal
and the impact of treatment. Presentación de simposio. Septiembre de
2008.
4. Silagy C, Stead LF, et. al. Nicotine replacement therapy for smoking
cessation. Cochrane Database of Systematic Reviews 1996, Issue 3. Art.
No.: CD000146. DOI: 10.1002/14651858.CD000146.pub3. Disponible:
http://www.cochrane.org/reviews/en/ab000...
5. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and
Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
U.S. Department of Health and Human Services. Public Health Service.
Mayo de 2008.
6. GSK Datos de archivo.
Contacto de Teresa Calanni, GolinHarris
Medios de EE.UU.: +1-312-729-4229, tcalanni@golinharris.com
Contacto Claire Dixon, UE, +44-20-8047-4296,
de medios Claire.E.Dixon@gsk.com
fuera de
EE.UU. Loic Andre, Colombia, +56-2-3829139,
Loic.Andre@gsk.com
Andrew Macmillen, Brazil, +54-11-4725-8925,
Andrew.N.Macmillen@gsk.com
Hader Perez, Mexico, +52-55-5483-8910,
Hader.A.Perez@gsk.com
Página web: http://www.gsk.com
EE.UU., Teresa Calanni de GolinHarris, +1-312-729-4229, tcalanni@golinharris.com, para GlaxoSmithKline; fuera de EE.UU., Claire Dixon, EU, +44-20-8047-4296, Claire.E.Dixon@gsk.com, o Loic Andre, Colombia, +56-2-3829139, Loic.Andre@gsk.com, o Andrew Macmillen, Brasil, +54-11-4725-8925, Andrew.N.Macmillen@gsk.com, o Hader Perez, México, +52-55-5483-8910, Hader.A.Perez@gsk.com, todos de GlaxoSmithKline
